Maximum Recommended Daily Dose of Adderall for Adults with ADHD

Regulatory and Guideline Limits

The American Academy of Child and Adolescent Psychiatry (AACAP) states that the FDA‑approved maximum daily dose of Adderall for adults with ADHD is 40 mg per day. 1
AACAP clinical practice guidelines note that, in carefully selected patients who do not respond to lower doses and who experience no adverse effects, daily doses may be increased to 60–65 mg on a rare basis. 1
The Physician’s Desk Reference, referenced by AACAP, lists 40 mg as the maximum total daily dose for amphetamines (and 60 mg for methylphenidate). 1
Expert consensus cited by AACAP often limits the upper range of amphetamine therapy to 40 mg per day when the dose is divided throughout the day. 1
Weight‑based dosing guidance from AACAP allows up to 0.9 mg/kg per day of amphetamine, which corresponds to roughly 40–65 mg per day for an average‑sized adult. [2][3]

AACAP recommends that clinicians document that symptoms remain uncontrolled at lower doses before considering doses above the standard maximum. 3
The same guideline requires that higher doses must not produce side effects such as weight loss, elevated blood pressure, or agitation. 3
When doses exceed standard recommendations, AACAP advises monitoring for signs of tolerance. 3
The consensus within AACAP is that doses exceeding the PDR‑listed upper limits should be used only on rare occasions. 1

AACAP suggests starting Adderall at 5 mg once or twice daily. [4][2]
The dose should be increased by 5–10 mg each week until adequate symptom control is achieved. 1
Most adults achieve therapeutic benefit within a 20–60 mg per day range, divided into 2–3 doses. 5
Because adults often require coverage for a longer waking day, AACAP notes that more frequent dosing may lead to higher total daily doses. [2][3]

Prior to exceeding 40 mg/day, AACAP recommends obtaining baseline blood pressure, pulse, height, and weight during a physical examination. [6][1]
Quarterly checks of blood pressure and pulse are advised for adults on stimulant therapy. [6][1]
Ongoing assessment should include screening for essential hypertension and cardiac arrhythmias before and during treatment. 6
At each visit, clinicians should monitor for weight loss, elevated blood pressure, and agitation. 3
If doses approach or surpass standard maximums, AACAP emphasizes evaluation for tolerance. 3

AACAP advises that if the top recommended dose does not provide sufficient benefit, clinicians should consider switching to an alternative stimulant (e.g., methylphenidate), adding psychosocial interventions such as cognitive‑behavioral therapy, or re‑evaluating comorbid conditions (depression, anxiety, substance use). [1][5]
When prescribing higher doses to adults with a comorbid substance‑use disorder, AACAP recommends heightened vigilance for abuse risk. 5